
Chinese biopharmaceutical company founded in 2011 in the Suzhou Industrial Park, Jiangsu and listed on the Hong Kong Stock Exchange, developing, manufacturing and commercialising high quality biologic medicines for oncology, metabolic, autoimmune and ophthalmic disease. Its marketed products include the PD-1 antibody sintilimab (Tyvyt) and biosimilars of bevacizumab, adalimumab and rituximab, and it runs large-scale antibody manufacturing to international GMP standards along with a broad clinical pipeline developed partly through partnerships with multinational pharmaceutical companies.
Unternehmensprofil ansehen
Bewertung hinterlassen